Report cover image

Global VMAT2 Inhibitor Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Jul 07, 2025
Length 102 Pages
SKU # APRC20339931

Description

Summary

According to APO Research, The global VMAT2 Inhibitor market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for VMAT2 Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for VMAT2 Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for VMAT2 Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of VMAT2 Inhibitor include Teva, Sandoz, Mylan, Zydus, Sun Pharmaceutical, Neurocrine Biosciences, Lupin, Hetero and Dr. Reddy's Laboratories, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for VMAT2 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VMAT2 Inhibitor.

The VMAT2 Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global VMAT2 Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

VMAT2 Inhibitor Segment by Company

Teva
Sandoz
Mylan
Zydus
Sun Pharmaceutical
Neurocrine Biosciences
Lupin
Hetero
Dr. Reddy's Laboratories
Chartwell Pharmaceuticals
Bionpharma
Bausch Health
Apotex
Actavis Laboratories
VMAT2 Inhibitor Segment by Type

Deutetrabenazine
Tetrabenazine
Valbenazine
VMAT2 Inhibitor Segment by Application

Chorea Caused by Huntington's Disease
Tardive Dyskinesia
Other
VMAT2 Inhibitor Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VMAT2 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of VMAT2 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VMAT2 Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of VMAT2 Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of VMAT2 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

102 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global VMAT2 Inhibitor Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global VMAT2 Inhibitor Sales Estimates and Forecasts (2020-2031)
1.3 VMAT2 Inhibitor Market by Type
1.3.1 Deutetrabenazine
1.3.2 Tetrabenazine
1.3.3 Valbenazine
1.4 Global VMAT2 Inhibitor Market Size by Type
1.4.1 Global VMAT2 Inhibitor Market Size Overview by Type (2020-2031)
1.4.2 Global VMAT2 Inhibitor Historic Market Size Review by Type (2020-2025)
1.4.3 Global VMAT2 Inhibitor Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America VMAT2 Inhibitor Sales Breakdown by Type (2020-2025)
1.5.2 Europe VMAT2 Inhibitor Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific VMAT2 Inhibitor Sales Breakdown by Type (2020-2025)
1.5.4 South America VMAT2 Inhibitor Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa VMAT2 Inhibitor Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 VMAT2 Inhibitor Industry Trends
2.2 VMAT2 Inhibitor Industry Drivers
2.3 VMAT2 Inhibitor Industry Opportunities and Challenges
2.4 VMAT2 Inhibitor Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by VMAT2 Inhibitor Revenue (2020-2025)
3.2 Global Top Players by VMAT2 Inhibitor Sales (2020-2025)
3.3 Global Top Players by VMAT2 Inhibitor Price (2020-2025)
3.4 Global VMAT2 Inhibitor Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global VMAT2 Inhibitor Major Company Production Sites & Headquarters
3.6 Global VMAT2 Inhibitor Company, Product Type & Application
3.7 Global VMAT2 Inhibitor Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global VMAT2 Inhibitor Market CR5 and HHI
3.8.2 Global Top 5 and 10 VMAT2 Inhibitor Players Market Share by Revenue in 2024
3.8.3 2023 VMAT2 Inhibitor Tier 1, Tier 2, and Tier 3
4 VMAT2 Inhibitor Regional Status and Outlook
4.1 Global VMAT2 Inhibitor Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global VMAT2 Inhibitor Historic Market Size by Region
4.2.1 Global VMAT2 Inhibitor Sales in Volume by Region (2020-2025)
4.2.2 Global VMAT2 Inhibitor Sales in Value by Region (2020-2025)
4.2.3 Global VMAT2 Inhibitor Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global VMAT2 Inhibitor Forecasted Market Size by Region
4.3.1 Global VMAT2 Inhibitor Sales in Volume by Region (2026-2031)
4.3.2 Global VMAT2 Inhibitor Sales in Value by Region (2026-2031)
4.3.3 Global VMAT2 Inhibitor Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 VMAT2 Inhibitor by Application
5.1 VMAT2 Inhibitor Market by Application
5.1.1 Chorea Caused by Huntington's Disease
5.1.2 Tardive Dyskinesia
5.1.3 Other
5.2 Global VMAT2 Inhibitor Market Size by Application
5.2.1 Global VMAT2 Inhibitor Market Size Overview by Application (2020-2031)
5.2.2 Global VMAT2 Inhibitor Historic Market Size Review by Application (2020-2025)
5.2.3 Global VMAT2 Inhibitor Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America VMAT2 Inhibitor Sales Breakdown by Application (2020-2025)
5.3.2 Europe VMAT2 Inhibitor Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific VMAT2 Inhibitor Sales Breakdown by Application (2020-2025)
5.3.4 South America VMAT2 Inhibitor Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa VMAT2 Inhibitor Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Teva
6.1.1 Teva Comapny Information
6.1.2 Teva Business Overview
6.1.3 Teva VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Teva VMAT2 Inhibitor Product Portfolio
6.1.5 Teva Recent Developments
6.2 Sandoz
6.2.1 Sandoz Comapny Information
6.2.2 Sandoz Business Overview
6.2.3 Sandoz VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sandoz VMAT2 Inhibitor Product Portfolio
6.2.5 Sandoz Recent Developments
6.3 Mylan
6.3.1 Mylan Comapny Information
6.3.2 Mylan Business Overview
6.3.3 Mylan VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Mylan VMAT2 Inhibitor Product Portfolio
6.3.5 Mylan Recent Developments
6.4 Zydus
6.4.1 Zydus Comapny Information
6.4.2 Zydus Business Overview
6.4.3 Zydus VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Zydus VMAT2 Inhibitor Product Portfolio
6.4.5 Zydus Recent Developments
6.5 Sun Pharmaceutical
6.5.1 Sun Pharmaceutical Comapny Information
6.5.2 Sun Pharmaceutical Business Overview
6.5.3 Sun Pharmaceutical VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sun Pharmaceutical VMAT2 Inhibitor Product Portfolio
6.5.5 Sun Pharmaceutical Recent Developments
6.6 Neurocrine Biosciences
6.6.1 Neurocrine Biosciences Comapny Information
6.6.2 Neurocrine Biosciences Business Overview
6.6.3 Neurocrine Biosciences VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Neurocrine Biosciences VMAT2 Inhibitor Product Portfolio
6.6.5 Neurocrine Biosciences Recent Developments
6.7 Lupin
6.7.1 Lupin Comapny Information
6.7.2 Lupin Business Overview
6.7.3 Lupin VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Lupin VMAT2 Inhibitor Product Portfolio
6.7.5 Lupin Recent Developments
6.8 Hetero
6.8.1 Hetero Comapny Information
6.8.2 Hetero Business Overview
6.8.3 Hetero VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Hetero VMAT2 Inhibitor Product Portfolio
6.8.5 Hetero Recent Developments
6.9 Dr. Reddy's Laboratories
6.9.1 Dr. Reddy's Laboratories Comapny Information
6.9.2 Dr. Reddy's Laboratories Business Overview
6.9.3 Dr. Reddy's Laboratories VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Dr. Reddy's Laboratories VMAT2 Inhibitor Product Portfolio
6.9.5 Dr. Reddy's Laboratories Recent Developments
6.10 Chartwell Pharmaceuticals
6.10.1 Chartwell Pharmaceuticals Comapny Information
6.10.2 Chartwell Pharmaceuticals Business Overview
6.10.3 Chartwell Pharmaceuticals VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Chartwell Pharmaceuticals VMAT2 Inhibitor Product Portfolio
6.10.5 Chartwell Pharmaceuticals Recent Developments
6.11 Bionpharma
6.11.1 Bionpharma Comapny Information
6.11.2 Bionpharma Business Overview
6.11.3 Bionpharma VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Bionpharma VMAT2 Inhibitor Product Portfolio
6.11.5 Bionpharma Recent Developments
6.12 Bausch Health
6.12.1 Bausch Health Comapny Information
6.12.2 Bausch Health Business Overview
6.12.3 Bausch Health VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Bausch Health VMAT2 Inhibitor Product Portfolio
6.12.5 Bausch Health Recent Developments
6.13 Apotex
6.13.1 Apotex Comapny Information
6.13.2 Apotex Business Overview
6.13.3 Apotex VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Apotex VMAT2 Inhibitor Product Portfolio
6.13.5 Apotex Recent Developments
6.14 Actavis Laboratories
6.14.1 Actavis Laboratories Comapny Information
6.14.2 Actavis Laboratories Business Overview
6.14.3 Actavis Laboratories VMAT2 Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Actavis Laboratories VMAT2 Inhibitor Product Portfolio
6.14.5 Actavis Laboratories Recent Developments
7 North America by Country
7.1 North America VMAT2 Inhibitor Sales by Country
7.1.1 North America VMAT2 Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America VMAT2 Inhibitor Sales by Country (2020-2025)
7.1.3 North America VMAT2 Inhibitor Sales Forecast by Country (2026-2031)
7.2 North America VMAT2 Inhibitor Market Size by Country
7.2.1 North America VMAT2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America VMAT2 Inhibitor Market Size by Country (2020-2025)
7.2.3 North America VMAT2 Inhibitor Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe VMAT2 Inhibitor Sales by Country
8.1.1 Europe VMAT2 Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe VMAT2 Inhibitor Sales by Country (2020-2025)
8.1.3 Europe VMAT2 Inhibitor Sales Forecast by Country (2026-2031)
8.2 Europe VMAT2 Inhibitor Market Size by Country
8.2.1 Europe VMAT2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe VMAT2 Inhibitor Market Size by Country (2020-2025)
8.2.3 Europe VMAT2 Inhibitor Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific VMAT2 Inhibitor Sales by Country
9.1.1 Asia-Pacific VMAT2 Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific VMAT2 Inhibitor Sales by Country (2020-2025)
9.1.3 Asia-Pacific VMAT2 Inhibitor Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific VMAT2 Inhibitor Market Size by Country
9.2.1 Asia-Pacific VMAT2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific VMAT2 Inhibitor Market Size by Country (2020-2025)
9.2.3 Asia-Pacific VMAT2 Inhibitor Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America VMAT2 Inhibitor Sales by Country
10.1.1 South America VMAT2 Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America VMAT2 Inhibitor Sales by Country (2020-2025)
10.1.3 South America VMAT2 Inhibitor Sales Forecast by Country (2026-2031)
10.2 South America VMAT2 Inhibitor Market Size by Country
10.2.1 South America VMAT2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America VMAT2 Inhibitor Market Size by Country (2020-2025)
10.2.3 South America VMAT2 Inhibitor Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa VMAT2 Inhibitor Sales by Country
11.1.1 Middle East and Africa VMAT2 Inhibitor Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa VMAT2 Inhibitor Sales by Country (2020-2025)
11.1.3 Middle East and Africa VMAT2 Inhibitor Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa VMAT2 Inhibitor Market Size by Country
11.2.1 Middle East and Africa VMAT2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa VMAT2 Inhibitor Market Size by Country (2020-2025)
11.2.3 Middle East and Africa VMAT2 Inhibitor Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 VMAT2 Inhibitor Value Chain Analysis
12.1.1 VMAT2 Inhibitor Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 VMAT2 Inhibitor Production Mode & Process
12.2 VMAT2 Inhibitor Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 VMAT2 Inhibitor Distributors
12.2.3 VMAT2 Inhibitor Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.